Significant Agreements - Novo Nordisk Share Purchase Agreement (Details) - USD ($) |
1 Months Ended | 3 Months Ended | |||
---|---|---|---|---|---|
Jul. 08, 2021 |
Dec. 31, 2022 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Dec. 31, 2023 |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Accounts receivable | $ 0 | $ 5,159,000 | |||
Novo Nordisk | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Share Purchase Agreement, Upfront Payment | $ 60,000,000 | ||||
Share Purchase Agreement, Potential Payment Upon Achievement of Development and Sales Milestones | 1,130,000,000 | ||||
Revenue from License and Intellectual Property, Share Purchase Agreement | 0 | $ 0 | |||
Milestone achievement, Clinical milestone | $ 40,000,000 | ||||
Accounts Receivable, after Allowance for Credit Loss | $ 0 | $ 0 | |||
Novo Nordisk | Transition services | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Revenue from License and Intellectual Property, Share Purchase Agreement | $ 700,000 |